公开(公告)号：EP3924374A1

公开(公告)日：2021-12-22

申请号：EP20706418.9

申请日：2020-02-13

申请人： Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) ,  Institució Catalana De Recerca I Estudis Avançats (ICREA) ,  Fundació Institut d'Investigació en Ciéncies de la Salut Germans Tiras i Pujol (IGTP)

发明人： MENÉNDEZ BUJÁN, Pablo ,  SANCHEZ MARTÍNEZ, Diego ,  BUENO UROZ, Clara ,  GUTIÉRREZ AGÜERA, Francisco ,  ROCA-HO, Heleia

IPC分类号： C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61P35/00 ,  A61K39/00

公开(公告)号：EP3696191A1

公开(公告)日：2020-08-19

申请号：EP19382104.8

申请日：2019-02-14

申请人： Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) ,  Institució Catalana De Recerca I Estudis Avançats (ICREA)

发明人： MENÉNDEZ BUJÁN, Pablo ,  SANCHEZ MARTÍNEZ, Diego ,  BUENO UROZ, Clara ,  GUTIÉRREZ AGÜERA, Francisco ,  ROCA-HO, Heleia

IPC分类号： C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61P35/00 ,  A61K39/00

摘要： Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. The present invention provides CARs comprising a CD1a-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLS.